XFOR X4 Pharmaceuticals Inc

Price (delayed)

$4.02

Market cap

$379.17M

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$3.32

Enterprise value

$239.51M

?
Relative Growth: Rel. Growth: 3
Relative Strength: Rel. Strength: 68
Relative Valuation: Rel. Valuation: 5
Relative Profitability: Rel. Profitability: 14

X4 Pharmaceuticals is a late-stage clinical biopharmaceutical company and a leader in the discovery and development of novel therapies for the treatment of diseases resulting from dysfunction of the CXCR4 ...

Highlights
The quick ratio has surged by 191% year-on-year
The EPS has dropped by 78% since the previous quarter
X4 Pharmaceuticals's gross profit has plunged by 75% from the previous quarter and by 71% YoY

Key stats

What are the main financial stats of XFOR

XFOR stock price

How has the X4 Pharmaceuticals stock price performed over time
Intraday
1.26%
1 week
-2.9%
1 month
-4.51%
1 year
-0.5%
YTD
0.5%
QTD
-2.66%

Financial performance

How have X4 Pharmaceuticals's revenue and profit performed over time
Revenue
$9.01M
Gross profit
$7.38M
Operating income
-$97.75M
Net income
-$99.72M
Gross margin
81.8%
Net margin
-1,106.3%
X4 Pharmaceuticals's gross profit has plunged by 75% from the previous quarter and by 71% YoY
The revenue has dropped by 74% since the previous quarter and by 71% year-on-year
X4 Pharmaceuticals's net income has decreased by 26% from the previous quarter
XFOR's operating income is down by 13% since the previous quarter

Price vs fundamentals

How does XFOR's price correlate with its fundamentals

Growth

What is X4 Pharmaceuticals's growth rate over time

Valuation

What is X4 Pharmaceuticals stock price valuation
P/E
N/A
P/B
2.17
P/S
56.32
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
26.57
The EPS has dropped by 78% since the previous quarter
The stock's price to book (P/B) is 84% less than its 5-year quarterly average of 13.2 but 13% more than its last 4 quarters average of 1.9
The equity has contracted by 10% from the previous quarter
The revenue has dropped by 74% since the previous quarter and by 71% year-on-year

Efficiency

How efficient is X4 Pharmaceuticals business performance
XFOR's return on invested capital is down by 40% since the previous quarter
The company's return on equity rose by 18% QoQ
XFOR's return on assets is down by 4.6% since the previous quarter

Dividends

What is XFOR's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for XFOR.

Financial health

How did X4 Pharmaceuticals financials performed over time
XFOR's total assets is 165% greater than its total liabilities
The quick ratio has surged by 191% year-on-year
The company's current ratio has surged by 175% YoY
The debt is 54% less than the equity
X4 Pharmaceuticals's debt to equity has plunged by 86% YoY but it has increased by 12% from the previous quarter
The equity has contracted by 10% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.